HCA at a glance
HCA Healthcare (HCA, SEC CIK 860730) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on July 28, 2026, an 8-K current report on July 29, 2026 and Form 4 insider filings as recently as August 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), HCA Healthcare (HCA) reported revenue of $75.6 billion (up 7.1% from FY2024) and net income of $6.8 billion. Diluted EPS was $28.33.
- As of June 30, 2026, 48 institutional investment managers tracked by SignalX reported holding HCA Healthcare (HCA) shares worth $20.2 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $75.6B
- +7.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 48 funds
- $20.2B · +2 vs prior quarter
- Latest 8-K
- Jul 29, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Operates healthcare facilities primarily through hospital services and affiliated outpatient centers
- No new products, services, or segments introduced or emphasized in 2026 filing
- Competitive positioning and strategy remain consistent with prior years; focus on governance and compliance highlighted
- Equity compensation plans include 6.439 million securities issuable, weighted average exercise price $194.62, 27.913 million shares available for future issuance
- Emphasis on enhanced governance disclosures and securities trading policy compliance, as detailed in proxy materials and investor relations website
Risk Factors
- Indebtedness $46.5B as of 12/31/2025, risk of default if financial covenants under senior unsecured credit facility are breached
- Workforce shortages and labor competition, including nurse-staffing ratio mandates in multiple states raising labor costs significantly
- Cybersecurity risks from increased AI-driven attacks and state-sponsored threat actors targeting health data and operational systems
- AI regulation risk: compliance with state laws California AB 3030, Utah AIPA, Colorado CAIA affecting generative AI use in patient care
- Key management dependency risk: unexpected loss of senior managers could disrupt operations despite succession planning efforts
Management Discussion & Analysis
- Operating cash flow $12.636B in 2025, up $2.122B from $10.514B in 2024 due to $1.319B net income increase and working capital improvements
- Capital expenditures $4.944B in 2025, slightly up from $4.875B in 2024; acquisitions $397M in 2025 vs $266M in 2024
- Financing cash use $8.550B in 2025 including $10.067B stock repurchases, $679M dividends; net debt increased $3.287B
- Debt totaled $46.492B in 2025, up from $43.031B in 2024; interest expense $2.248B vs $2.061B with 5.0% average effective rate both years
- Management expects 2026 capex $5.0B-$5.5B, sufficient liquidity from operations, $5.779B credit facility available, and access to debt markets
AI summary of the HCA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Emergency room visits 2,526,147, up from 2,439,763 YoY
- Outpatient surgeries 246,947, down from 258,365 YoY
- Inpatient surgeries 133,041, down from 136,122 YoY
- Days revenues in accounts receivable 55 vs 51 YoY
- Outpatient revenues 34% of patient revenues vs 38% YoY, impacted by Florida directed payments
Risk Factors
- No material risk-factor changes from the December 31, 2025 10-K
- Financial risk: $7.210 billion remaining under the January 2026 share-repurchase authorization
- Debt risk: $4.700% senior notes due 2031 issued April 30, 2026
- Debt risk: $5.000% senior notes due 2033 and $5.300% senior notes due 2036 issued April 30, 2026
AI summary of the HCA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Commercial paper capacity doubled from $4.0B to $8.0B outstanding
- Unsecured notes issued by HCA Inc., with unconditional HCA Healthcare guarantee
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued July 24, 2026
Item 7.01: Regulation FD Disclosure
- HCA disclosed second-quarter 2026 operating results for the period ended June 30, 2026
- Market-relevant financial details are contained in Exhibit 99.1 accompanying the July 24, 2026 press release
Item 8.01: Other Events
- Quarterly cash dividend of $0.78 per common share declared
- Payment scheduled for September 30, 2026
Item EX-99.1: Item EX-99.1
- 2Q revenue rose 8.7% to $20.230B; diluted EPS increased 11.6% to $7.62 despite payer-mix pressure
- Uninsured patients reduced pretax income approximately $400M; exchange-related headwind estimate widened to $1.000B–$1.200B for 2026
Item 2.02: Results of Operations and Financial Condition
- Preliminary second-quarter results for period ended June 30, 2026
- HCA issued results announcement on July 14, 2026
Item 7.01: Regulation FD Disclosure
- Preliminary Q2 2026 operating results for quarter ended June 30, 2026
- Press release issued July 14, 2026 under Regulation FD
Item EX-99.1: Item EX-99.1
- Preliminary Q2 revenue $20.230B versus $18.605B; net income $1.699B versus $1.653B; EPS $7.62 versus $6.83
- Same-facility admissions rose 2.5%, equivalent admissions 2.7%, and ER visits 3.6%; inpatient and outpatient surgeries declined 2.3% and 3.4%
AI summaries of HCA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HCA
Don't miss the next HCA filing
- Alerts as it files. A push when HCA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HCA, by share count.
- Ask anything. An AI agent that reads every HCA filing and answers with sources.
HCA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| McAlevey Michael R | J | Aug 26, 2026 | 7,769 | $429.00 |
| Marks Mike A | G | May 7, 2026 | 3,336 | - |
| Marks Mike A | G | May 7, 2026 | 3,336 | - |
| Smith Andrea B | A | Apr 28, 2026 | 509 | - |
| CHIDSEY JOHN | A | Apr 28, 2026 | 809 | - |
| Frist William R | A | Apr 28, 2026 | 809 | - |
| Johnston Hugh F | A | Apr 28, 2026 | 809 | - |
| DEPARLE NANCY ANN | A | Apr 28, 2026 | 509 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $65.0B | $70.6B | $75.6B |
| Net Income | $5.2B | $5.8B | $6.8B |
| Net Margin | 8.1% | 8.2% | 9.0% |
| Balance Sheet | |||
| Total Assets | $56.2B | $59.5B | $60.7B |
| Equity | -$1.8B | -$2.5B | -$6.0B |
| ROE | -295.5% | -230.5% | -112.6% |
| Per Share | |||
| EPS | - | $22.00 | $28.33 |
| Cash Flow | |||
| Operating CF | $9.4B | $10.5B | $12.6B |
| CapEx | $4.7B | $4.9B | $4.9B |
Source: XBRL data in HCA Healthcare (HCA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate HCA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 48 | $20.18B |
| Q1 2026 | 46 | $26.62B |
| Q4 2025 | 47 | $26.15B |
| Q3 2025 | 51 | $25.69B |
| Q2 2025 | 48 | $23.35B |
| Q1 2025 | 43 | $16.54B |
| Q4 2024 | 40 | $11.47B |
| Q3 2024 | 36 | $7.67B |
- Goldman Sachs Group+328.2K (+15%)
- Morgan Stanley+291.9K (+13%)
- Wells Fargo & Co+146.5K (+76%)
- Invesco Ltd+91.1K (+6%)
- D.E. Shaw & Co+89.5K (+179%)
- FMR LLC (Fidelity)−2.77M (-63%)
- BlackRock−359.7K (-3%)
- T. Rowe Price Group−264.5K (-51%)
- Franklin Resources−190.8K (-16%)
- JPMorgan Chase & Co−176.1K (-7%)
- Renaissance Technologies LLC+18.6K
- Blackstone Group+3.3K
- Marex Group plc+2.0K
- StoneX Group Inc.+710
- Viking Global Investors−1.08M
- Two Sigma Investments−1.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 359 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HCA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 28, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 10-Q | Jul 28, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 24, 2026 | - | Analysis | - |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | May 11, 2026 | - | - | |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| SC 13G | Apr 30, 2026 | - | - | |
| 10-Q | Apr 29, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 8-K | Apr 24, 2026 | - | Analysis | - |
| 8-K | Feb 25, 2026 | - | Analysis | - |
| 4 | Feb 12, 2026 | - | - | |
| 4 | Feb 12, 2026 | - | - | |
| 4 | Feb 12, 2026 | - | - |
Related Health Care companies
- ARDT · Ardent Health, Inc.Services-General Medical & Surgical Hospitals, NEC
- CYH · COMMUNITY HEALTH SYSTEMS INCServices-General Medical & Surgical Hospitals, NEC
- SGRY · Surgery Partners, Inc.Services-General Medical & Surgical Hospitals, NEC
- UHS · Universal Health ServicesServices-General Medical & Surgical Hospitals, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
HCA SEC filings: frequently asked questions
Which institutions hold HCA stock?
As of June 30, 2026, the largest HCA Healthcare (HCA) holders among the 13F filers tracked by SignalX were BlackRock ($5.1 billion), Vanguard Capital Management LLC ($4.0 billion), State Street Corp ($2.9 billion), Vanguard Portfolio Management LLC ($1.1 billion), Morgan Stanley ($1.0 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HCA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), HCA Healthcare (HCA) reported revenue of $75.6 billion (up 7.1% from FY2024) and net income of $6.8 billion. Diluted EPS was $28.33. The figures come from the XBRL data in the 10-K.
What are the main risks in HCA's latest 10-K?
In the 10-K filed February 10, 2026, HCA Healthcare (HCA) flagged: Indebtedness $46.5B as of 12/31/2025, risk of default if financial covenants under senior unsecured credit facility are breached. Workforce shortages and labor competition, including nurse-staffing ratio mandates in multiple states raising labor costs significantly. (AI summary of the Risk Factors section.)
What did HCA report in its latest 8-K?
HCA Healthcare (HCA) filed an 8-K on July 29, 2026 reporting Item 8.01 (Other Events). Commercial paper capacity doubled from $4.0B to $8.0B outstanding.
What are the latest HCA SEC filings?
HCA Healthcare (HCA) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on July 28, 2026, an 8-K current report on July 29, 2026 and a Form 4 insider filing on August 28, 2026.
What is HCA's SEC CIK number?
HCA Healthcare (HCA)'s SEC Central Index Key (CIK) is 860730. EDGAR lists every HCA filing under that number.
Ask anything about HCA
The research agent reads HCA's filings, financials, insider trades and 13F holders, then answers with sources.